Technology Platform

We are leveraging our proprietary technology platforms to develop a novel class of precision oncology therapeutics designed to address clinically validated drug targets.

While the traditional class of TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, their use to treat solid tumors has presented limitations such as overactivation of the immune system leading to cytokine release syndrome (CRS), on-target, healthy tissue toxicities and poor pharmacokinetics (PK) leading to short half-life.

Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional TCE toxicity and efficacy limitations. TRACTrs and TRACIrs are purposefully designed to enhance tumor-specific activation with crossover pharmacokinetics to provide medicines with improved safety, dosing and efficacy.

Each of our TRACTrs is comprised of a tumor antigen-binding domain and a T cell binding domain (CD3), while each of our TRACIrs utilizes a tumor antigen-binding domain linked to a T cell costimulatory CD28 binding domain.

The CD3 and CD28 binding domain is always protected by a domain-optimized peptide mask that is covalently bound to the CD3 or CD28 binding domain by way of a tumor specific cleavable peptide linker.

The mask inhibits T cell binding to the CD3 or CD28 domain, until it is removed at the tumor via tumor specific proteases. To extend the half-life of the TRACTr and TRACIr, an albumin binding domain is attached to one of the domain masks via a tumor cleavable peptide linker. Hence, all masks and the albumin binding domain are removed at the tumor.

Both of our novel TRACTr and TRACIr platforms leverage our proprietary technology that is designed to offer the following features:

Accuracy

Selective cleavage of the TRACTr or TRACIr peptide masks in the tumor microenvironment forms the active TCE or T cell co-stimulatory molecules. These active molecules have short half-lives and are rapidly cleared from the body to avoid toxicity if they escape the tumor microenvironment.

Stability

Domain masks and albumin binding domain linkers are designed to be stable outside of the tumor microenvironment. This keeps the drug candidate stable in the blood stream and provides a long serum half-life before activation.

Activity

Demasked TCE’s are highly active, enabling effective therapy at low levels of tumor target expression

Modularity

Several elements of our underlying technology make it possible to leverage the foundation of our existing drug programs to rapidly develop new drug candidates.

Manufacturability

The TRACTr and TRACIr manufacturing processes are similar to monoclonal antibody manufacturing and thereby have the potential to deliver cost-effective drug candidates.

We have a range of immuno-oncology programs currently in development.

See our pipeline